NASDAQ NMS - GLOBAL MARKET · TLSA
+3.25% · +$0.0300 · Vol 534.9K
After hours · updated 18:31:43 ET
Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd

Biotechnology
$0.9350
Card
Relationship Map

Follow $TLSA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $TLSA by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
TLSA
Tiziana Life Sciences Ltd
Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

38/ 100
Veridion Score
Lower range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 4 of 6 factors measured · Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is TLSA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading TLSA catalysts
About Tiziana Life Sciences Ltd
Biotechnology
Listed since
2018
Employees
10
Country
GB

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9400
Day high
$0.9499
Day low
$0.9000
Previous close
$0.9056
52W high
$2.29
-59.17% from high
52W low
$0.7701
11% of range
Market cap
$115.2M
EPS
$-0.1551
Beta
1.11
Shares out
127.3M
Volume
534.9K
0.63× rel vol
Avg volume
844.5K
VWAP
$0.9162
Price history computed in-house
1W
+5.03%
1M
-17.98%
3M
-19.40%
1Y
-48.63%
YTD
-37.25%
SMA 50 $1.01 · below
SMA 200 $1.29 · below
52W position 11%

TLSA overview

Loading financial statements
Loading TLSA Form 4 filings
Public disclosures

Congress activity in TLSA

No receipt-qualified Congressional disclosure is present for TLSA in the cached public ledger.

Federal contracts

TLSA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for TLSA in this window.
Lobbying spend

TLSA lobbying filings, year to date.

Registered lobbying filings matched to Tiziana Life Sciences Ltd.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for TLSA in this window.
Loading news for TLSA
Analyst ratings
Sovereign unlock shows live analyst consensus for TLSA.
Options
Sovereign unlock shows live options positioning for TLSA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.